Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy (HPV-BIOFRO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France
- Institut Claudius Regaud
-
Toulouse, France
- CHU Toulouse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presents a suspicious lesion of the amygdala region
- Have a biopsy of the oropharynx planned in the operating room.
Exclusion Criteria:
- Pregnant Patient.
- Against anesthetic or surgical indication for endoscopy of the upper aerodigestive tract.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: patient with suspected lesions of the tonsillar region
patients will have a tonsil biopsy and a smear
|
Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
The smears are made in consultation a fortnight before performing endoscopic examination.
They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the correlation between the two sampling methods
Time Frame: 1 month
|
the correlation between the two sampling methods (smear and biopsy), defined by the probability of positive correlation and the negative concordance probability.
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of concordance for the detection of HPV between biopsy and smear
Time Frame: 1 month
|
1 month
|
|
|
the overall agreement
Time Frame: 1 month
|
the overall agreement, assessed by kappa Cohen.
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Benjamin VAIREL, Doctor, CHU Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 10 153 02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.